Tempus AI teams with Northwestern to advance Alzheimer’s research

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a technology company with a market capitalization of $12.25 billion and trading near $71 per share, announced Thursday a multi-year collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to advance Alzheimer’s disease research through artificial intelligence. According to InvestingPro data, the company has demonstrated impressive momentum with a 76% return over the past year.

The partnership will utilize Tempus’ AI-powered data analytics platform, Lens, to analyze the Center’s genomic data repository. The teams aim to identify genomic patterns that could enhance understanding of Alzheimer’s disease, investigate affected gene and cell types, and potentially accelerate therapeutic development.

"By integrating our AI platform with the Center’s pioneering work in neurogenomics, we are opening new avenues for discovery," said Ryan Fukushima, Chief Operating Officer at Tempus.

David Gate, PhD, assistant professor in the Ken and Ruth Davee Department of Neurology at Feinberg and head of The Abrams Research Center on Neurogenomics, stated, "We share a commitment to deepen our understanding of the genomic underpinnings of Alzheimer’s disease and accelerate the development of more targeted, effective interventions."

Tempus describes itself as a technology company that applies artificial intelligence to healthcare, maintaining a large library of multimodal data to support precision medicine solutions.

The collaboration represents an effort to address what the companies characterize as one of medicine’s most complex challenges, according to the press release statement. Financial terms of the partnership were not disclosed. Investors can access a comprehensive Pro Research Report on Tempus AI, along with detailed financial metrics and expert analysis, through InvestingPro’s extensive coverage of over 1,400 US stocks.

In other recent news, Tempus AI, Inc. reported the approval of all proposals at its 2025 Annual Meeting of Stockholders, including the election of nine directors and the appointment of PricewaterhouseCoopers LLP as the independent auditor. The shareholders also supported a proposal to reincorporate from Delaware to Nevada, although the Board retains discretion over this move. Tempus AI introduced a new liquid biopsy assay, xM for TRM, at the ASCO Annual Meeting, designed to monitor treatment responses in cancer patients. This assay could offer early insights into the effectiveness of immune-checkpoint inhibitor therapy. In collaboration news, Tempus AI partnered with Verastem Oncology to develop a diagnostic test for recurrent low-grade serous ovarian cancer. Additionally, Tempus AI announced a multi-year partnership with Boehringer Ingelheim to enhance cancer treatment research using its AI platform and data library. Lastly, TD Cowen analysts maintained their Buy rating on Tempus AI stock despite a recent short report, citing discussions with the company’s CFO to address investor concerns.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.